

## Product datasheet for **TL314524V**

### **BAG3 Human shRNA Lentiviral Particle (Locus ID 9531)**

#### **Product data:**

<b>Product Type:</b>	shRNA Lentiviral Particles
<b>Product Name:</b>	BAG3 Human shRNA Lentiviral Particle (Locus ID 9531)
<b>Locus ID:</b>	9531
<b>Synonyms:</b>	BAG-3; BIS; CAIR-1; MFM6
<b>Vector:</b>	pGFP-C-shLenti (TR30023)
<b>Format:</b>	Lentiviral particles
<b>Components:</b>	BAG3 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
<b>RefSeq:</b>	<a href="#">NM_004281</a> , <a href="#">NM_004281.1</a> , <a href="#">NM_004281.2</a> , <a href="#">NM_004281.3</a> , <a href="#">BC006418</a> , <a href="#">BC006418.1</a> , <a href="#">BC014656</a> , <a href="#">BC107786</a> , <a href="#">NM_004281.4</a>
<b>UniProt ID:</b>	<a href="#">O95817</a>
<b>Summary:</b>	BAG proteins compete with Hip for binding to the Hsc70/Hsp70 ATPase domain and promote substrate release. All the BAG proteins have an approximately 45-amino acid BAG domain near the C terminus but differ markedly in their N-terminal regions. The protein encoded by this gene contains a WW domain in the N-terminal region and a BAG domain in the C-terminal region. The BAG domains of BAG1, BAG2, and BAG3 interact specifically with the Hsc70 ATPase domain in vitro and in mammalian cells. All 3 proteins bind with high affinity to the ATPase domain of Hsc70 and inhibit its chaperone activity in a Hip-repressible manner. [provided by RefSeq, Jul 2008]
<b>shRNA Design:</b>	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).